Assess Risk and Avoid Adverse CV Events and Post-Marketing Liabilities
- Arlington, VA
Adverse cardiovascular events may pose a considerable threat during preclinical and clinical drug development, as well as in the post-marketing phase. As a result, the need for extensive cardiovascular risk assessment is increasingly recognized as critically important for successful drug development. CBI and Applied Clinical Trials 6th Annual Cardiovascular Risk Assessment Summit provides us with the opportunity to review the most effective strategies for understanding and assessing cardiovascular risk.
Topics for discussion include:
- Guiding translational research into the clinic
- Identifying acceptable ranges of blood pressure and heart rate change
- Assessing automated algorithms in ECG analytics
- Minimizing post-marketing cardiovascular risk occurrence
For sponsorship/exhibit opportunities, please email Alexa Moore at [email protected].
To submit abstracts for speaking on the program, please email Suzanne Thelen at [email protected].
Co-Sponsored by: Cardiocore
Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for nineteen years. Services include centralized electrocardiography (ECG), ambulatory blood pressure monitoring (ABPM), echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s global headquarters is based in Washington, DC, and the company’s additional core lab facilities are based in South San Francisco, California, London, England and Singapore. For more information, visit